Affordable Access

deepdyve-link
Publisher Website

Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination.

Authors
  • Sheen, Youn H1, 2
  • Kizilbash, Sarah1, 3
  • Ryoo, Eell1, 4
  • Wi, Chung-Il1
  • Park, Miguel5
  • Abraham, Roshini S6
  • Ryu, Euijung7
  • Divekar, Rohit5
  • Juhn, Young8
  • 1 Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • 2 Department of Pediatrics, CHA University School of Medicine, Seoul, Korea. , (North Korea)
  • 3 Department of Pediatrics, School of Medicine, University of Minnesota, Twin Cities, MN, USA.
  • 4 Department of Pediatrics, Gil Hospital, Gachon University, Incheon, Korea. , (North Korea)
  • 5 Division of Allergic Diseases, Mayo Clinic, Rochester, MN, USA.
  • 6 Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • 7 Department of Health Sciences and Research, Mayo Clinic, Rochester, MN, USA.
  • 8 Department of Pediatric and Adolescent Medicine/Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Type
Published Article
Journal
Journal of Asthma
Publisher
Informa UK (Taylor & Francis)
Publication Date
Apr 01, 2020
Volume
57
Issue
4
Pages
381–390
Identifiers
DOI: 10.1080/02770903.2019.1575394
PMID: 30784333
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Objective: Asthma poses an increased risk for serious pneumococcal disease, but little is known about the influence of asthma status on the 23-valent serotype-specific pneumococcal antibody response. We examined differences in antibody titers between pre- and post-vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in relation to asthma status. Methods: Asthma status was retrospectively ascertained by the Predetermined Asthma Criteria in an existing vaccine cohort through comprehensive medical record review. Twenty-three serotype-specific pneumococcal antibody titers measured at baseline and 4-6 weeks post-vaccination were analyzed. Vaccine responses to PPSV-23 were calculated from pre- to post-vaccine titers for each of the serotypes. Results: Of the 64 eligible and enrolled subjects, 18 (28%) had asthma. Controls (i.e., subjects without asthma) demonstrated a statistically significant fold change response compared to their baseline for all serotypes, while those with asthma did not mount a significant response to serotypes 7F, 22F, and 23F. The overall vaccine response as measured by fold change over baseline was lower in subjects with asthma than controls. Conclusions: Poorer humoral immune responses to PPSV-23 as measured by fold change were more likely to be observed in subjects with asthma compared to controls. We recommend the consideration of asthma status when interpreting vaccine response for immune competence workup through larger studies. Further studies are warranted to replicate these findings.

Report this publication

Statistics

Seen <100 times